To assess the safety of a single intradermal injection of 5 x 107pfu MVA85A, when administered to healthy subjects. The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events (AEs).
To assess the immunogenicity of a single vaccination with MVA85A in healthy subjects. The specific endpoints for immunogenicity will be markers of cell-mediated immunity as outlined above
12 Years to 50 Years (Child, Adult)
April 16, 2007
August 7, 2008
University Cape Town Cape Town, South Africa
† Study has passed its completion date and status has not been verified in more than two years.